Pharmacy Times®
Specialty Pharmacy Times
  • Keeping an Eye on Hepatitis C Virus Drug Approvals
  • Community Specialty Pharmacy: The Time Is Now!
  • Specialty Pipeline Highlights
  • Evaluating and Elevating Specialty Pharmacists Through Certification
  • How Will Specialty Pharmacy Be Affected By Cost Containment?
  • Psoriatric Arthritis: An Overview
Enterovirus Cases Spread to the Northeast
Davy James, Associate Editor
Respiratory illness hits New York and Connecticut bringing total number of states affected to 21.
Specific Baldness Pattern Associated with Increased Prostate Cancer Risk
Davy James, Associate Editor
Baldness on front and crown of head linked to increased chance of developing aggressive prostate cancer.
Hemophilia B Treatment Approved for Pediatric Patients
Davy James, Associate Editor
Rixubis found to be effective in children under the age of 12.
Opsumit by Actelion Pharmaceuticals US, Inc
Michael R. Page, PharmD, RPh
Opsumit (macitentan) was approved to reduce the risk of hospitalization and delay disease progression in patients with WHO group I pulmonary arterial hypertension.
Zydelig by Gilead Sciences, Inc
Michael R. Page, PharmD, RPh
The FDA has approved Zydelig (idelalisib) tablets for the later-line treatment of 3 types of cancer, including chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma.
Featured Video
Consumerism in the New Era of Specialty Prescriptions
Bill Barre, RPh, vice president of business development at MedImpact Healthcare Systems, how specialty pharmacies can meet the demands of consumerism in the new era of prescription fulfillment.
Industry Guide
We've created this Industry Guide with close to 300 companies and organizations as a one-stop guide for industry stakeholders in the specialty pharmacy space.
Current Issue
Volume: 5
Number: 4
Conference Calendar
â—„        September 2014        â–º
Featured Company Profile
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Pharmacy Times 2006-2013
Intellisphere, LLC. All Rights Reserved.